Shares of neurotechnology medical company, Helius Medical were up 10% on Wednesday to trade as high as $8.50 per share after the company reported it has teamed with Lovell Government Services , an SBA-certified Service Disabled Veteran Owned Small Business to make the company’s portable neuromodulation stimulator or PoNS device available to federal healthcare systems. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSDT:
- Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
- Helius Medical reports Q4 EPS ($1.47), consensus ($3.77)
- Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
- Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
- Helius Medical initiates open-label study for registrational program in stroke
